The significant drop in Humana's Medicare Advantage Star Ratings from 94% to 25% for plans rated 4 stars or above will reduce quality bonus payments in 2026. This is a critical issue for Humana's future revenue, leading to a likely negative short-term impact on its stock price as the company seeks to mitigate the financial effects.